Notice of Class Action Lawsuit for uniQure Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application due to the need for additional studies, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.260
Low
33.00
Averages
49.88
High
70.00
Current: 15.260
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application due to the need for additional studies, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Faruqi & Faruqi Investigates Potential Claims Against UniQure
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025.
- Investor Contact Information: The firm encourages investors who suffered losses during this period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights.
- Class Action Reminder: Faruqi & Faruqi reminds investors of the April 13, 2026, deadline to seek the role of lead plaintiff in a federal securities class action filed against UniQure, urging timely action.
- Market Impact Assessment: This investigation may negatively affect UniQure's stock price, prompting investors to monitor legal developments and their potential implications for the company's future.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Update: Hagens Berman is updating its investigation into uniQure N.V. regarding a securities class action lawsuit for the period from September 24 to October 31, 2025, reminding investors to submit Lead Plaintiff applications by April 13, 2026, to represent others in the litigation.
- Serious FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could negatively impact the company's reputation and future research prospects.
- Overview of Allegations: The class action, Scocco v. uniQure N.V., alleges that uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's future outlook.
- Whistleblower Incentives: Hagens Berman encourages individuals with insider information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to participate in the investigation and further impacting uniQure's legal situation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to seek lead plaintiff status by April 13, 2026, highlighting significant legal risks and potential financial repercussions for the company.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, indicating a severe loss of market confidence in the company's prospects and potentially leading to diminished investor trust.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, suggesting that the ongoing legal challenges may impact the company's future financing capabilities and market reputation, necessitating cautious investor responses.
- Uncertain Company Outlook: Throughout the lawsuit period, uniQure failed to adequately disclose the FDA approval status of its clinical trials, resulting in weakened investor confidence in its drug development, which could adversely affect future investment decisions and market performance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially damaging the company's reputation in clinical trials.
- Legal Action: uniQure is facing a securities class action lawsuit alleging that it failed to disclose the lack of regulatory consensus with the FDA during the Class Period from September 24 to October 31, 2025, leading to a 49% stock drop on November 3, which resulted in significant investor losses.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, highlighting the legal and regulatory pressures on the company that may impact its future financing and market performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA was dissatisfied with the timeline for its BLA submission for AMT-130, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting a pessimistic market sentiment regarding the company's prospects.
- Investor Action Guidance: Affected uniQure investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, highlighting investor concerns over corporate governance and transparency in the wake of the lawsuit.
- Law Firm Credentials: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud litigation, having recovered over $25 billion for clients, demonstrating its strong capabilities and influence in investor protection efforts.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application due to the need for additional studies, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Faruqi & Faruqi Investigates Potential Claims Against UniQure
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025.
- Investor Contact Information: The firm encourages investors who suffered losses during this period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights.
- Class Action Reminder: Faruqi & Faruqi reminds investors of the April 13, 2026, deadline to seek the role of lead plaintiff in a federal securities class action filed against UniQure, urging timely action.
- Market Impact Assessment: This investigation may negatively affect UniQure's stock price, prompting investors to monitor legal developments and their potential implications for the company's future.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Update: Hagens Berman is updating its investigation into uniQure N.V. regarding a securities class action lawsuit for the period from September 24 to October 31, 2025, reminding investors to submit Lead Plaintiff applications by April 13, 2026, to represent others in the litigation.
- Serious FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could negatively impact the company's reputation and future research prospects.
- Overview of Allegations: The class action, Scocco v. uniQure N.V., alleges that uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's future outlook.
- Whistleblower Incentives: Hagens Berman encourages individuals with insider information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to participate in the investigation and further impacting uniQure's legal situation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to seek lead plaintiff status by April 13, 2026, highlighting significant legal risks and potential financial repercussions for the company.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, indicating a severe loss of market confidence in the company's prospects and potentially leading to diminished investor trust.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, suggesting that the ongoing legal challenges may impact the company's future financing capabilities and market reputation, necessitating cautious investor responses.
- Uncertain Company Outlook: Throughout the lawsuit period, uniQure failed to adequately disclose the FDA approval status of its clinical trials, resulting in weakened investor confidence in its drug development, which could adversely affect future investment decisions and market performance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially damaging the company's reputation in clinical trials.
- Legal Action: uniQure is facing a securities class action lawsuit alleging that it failed to disclose the lack of regulatory consensus with the FDA during the Class Period from September 24 to October 31, 2025, leading to a 49% stock drop on November 3, which resulted in significant investor losses.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, highlighting the legal and regulatory pressures on the company that may impact its future financing and market performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA was dissatisfied with the timeline for its BLA submission for AMT-130, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting a pessimistic market sentiment regarding the company's prospects.
- Investor Action Guidance: Affected uniQure investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, highlighting investor concerns over corporate governance and transparency in the wake of the lawsuit.
- Law Firm Credentials: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud litigation, having recovered over $25 billion for clients, demonstrating its strong capabilities and influence in investor protection efforts.
See More
